Agenus (NASDAQ:AGEN) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of Agenus (NASDAQ:AGEN) in a note issued to investors on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Several other brokerages also recently commented on AGEN. B. Riley dropped their target price on shares of Agenus from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, March 18th. HC Wainwright restated a “buy” rating and set a $160.00 price objective on shares of Agenus in a report on Thursday, March 14th.

Agenus Trading Down 8.0 %

AGEN stock opened at $4.97 on Wednesday. Agenus has a 1 year low of $4.78 and a 1 year high of $42.60. The company has a fifty day simple moving average of $11.86 and a 200 day simple moving average of $14.29. The firm has a market cap of $104.12 million, a PE ratio of -0.35 and a beta of 1.26.

Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) EPS for the quarter, missing the consensus estimate of ($0.40) by ($2.20). The company had revenue of $83.80 million for the quarter, compared to analysts’ expectations of $54.21 million. As a group, analysts forecast that Agenus will post -8.21 EPS for the current fiscal year.

Insider Transactions at Agenus

In related news, insider Garo H. Armen acquired 25,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were bought at an average price of $13.00 per share, for a total transaction of $325,000.00. Following the acquisition, the insider now owns 31,298 shares in the company, valued at approximately $406,874. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 4.80% of the company’s stock.

Institutional Trading of Agenus

Several hedge funds have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. raised its holdings in Agenus by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 558,606 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 13,604 shares during the last quarter. Powell Investment Advisors LLC grew its position in shares of Agenus by 21.8% during the 1st quarter. Powell Investment Advisors LLC now owns 243,500 shares of the biotechnology company’s stock worth $141,000 after buying an additional 43,500 shares during the period. Key Client Fiduciary Advisors LLC raised its stake in shares of Agenus by 38.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 858,969 shares of the biotechnology company’s stock worth $498,000 after buying an additional 236,500 shares during the last quarter. Ables Iannone Moore & Associates Inc. bought a new position in Agenus in the fourth quarter valued at approximately $65,000. Finally, Vanguard Group Inc. grew its holdings in Agenus by 12.4% during the 4th quarter. Vanguard Group Inc. now owns 30,266,890 shares of the biotechnology company’s stock worth $25,058,000 after acquiring an additional 3,328,451 shares during the period. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.